The company anticipates total revenue for the quarter to range between $32 million and $34 million, which includes $5 million to $7 million from its strategic collaboration with Alcon. The exact figures will be disclosed in the full financial results in August 2026.
The collaboration with Alcon focuses on developing and commercializing light-adjustable Presbyopia-Correcting Intraocular Lenses. Additionally, RxSight is advancing its Light Adjustable Technology™ platform, planning intermediate-term launches of new LAL®, LAL +®, and LAL Toric lenses, which promise improved workflow and reduced post-operative treatments.
For the full year 2026, RxSight projects revenue between $140 million and $160 million, including sales from the Alcon collaboration. Sales are expected to be $110 million to $120 million, which is below the previous forecast of $120 million to $135 million.
However, the company anticipates a gross margin of 73 percent to 75 percent, surpassing earlier guidance of 70 percent to 72 percent. Operating expenses are projected to be at the high end of $150 million to $160 million, consistent with prior estimates.
Dr. Ron Kurtz, Chief Executive Officer and President, said, “While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world.”
